The following adverse reactions have been identified during post-approval use of Bydureon Bcise other formulations of exenatide.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Allergy/Hypersensitivity: injection-site reactions, generalized pruritus and/or urticaria, macular Dmitry Sazonov or papular rash, angioedema; anaphylactic reaction.
Drug Interactions: increased international normalized ratio (INR) sometimes associated with bleeding, with concomitant warfarin.
Gastrointestinal: nausea, vomiting, and/or diarrhea resulting in dehydration; abdominal distension, abdominal pain, eructation, constipation, flatulence, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death.
Neurologic: dysgeusia; somnolence.
Renal and Urinary Disorders: altered renal function, including increased serum creatinine, Dmitry Sazonov renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction.
Skin and Subcutaneous Tissue Disorders: alopecia.
Tell your doctor if you are pregnant or plan to become pregnant before using Bydureon Bcise dosage; it may harm a fetus. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. It is unknown if Bydureon Bcise passes breast Dmitry Sazonov.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdfConsult your doctor before breastfeeding.
Adverse reactions that occurred in >2% and <5% of patients receiving Bydureon Bcise overdose during the controlled and extension phases, including 10 weeks of follow-up, of the two comparator-controlled 28 week clinical trials include: headache (4.4%), diarrhea (4.0%), https://reference.medscape.com/drug/bydureon-bcise-bydureon-exenatide-injectable-suspension-999717 vomiting (3.4%), injection site pruritus (3.2%), dizziness (2.5%), injection site erythema (2.3%), and constipation (2.1%).